Stock comparison
BridgeBio Pharma
Harmony Biosciences Holdings
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BBIO
BridgeBio Pharma
Market cap
$13.54B
Sector
Healthcare
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
Overall winner
Harmony Biosciences Holdings HRMY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BBIO | HRMY | Winner |
|---|---|---|---|
| Warren Buffett | 24F | 67B | HRMY |
| Benjamin Graham | 18F | 60C | HRMY |
| Philip Fisher | 43D | 75B | HRMY |
| Peter Lynch | 29F | 62C | HRMY |
| Joel Greenblatt | 2F | 28F | HRMY |
| Charlie Munger | 36D | 62C | HRMY |
| Terry Smith | 33F | 67B | HRMY |
Side-by-side metrics
| Metric | BBIO | HRMY |
|---|---|---|
| Market cap | $13.54B | $1.75B |
| P/E (TTM) | - | 11.8x |
| EV/EBIT | - | 6.4x |
| ROIC (TTM) | -57.94% | 12.5% |
| Gross margin | 93.78% | 76.55% |
| Net margin | -125.17% | 16.2% |
| Revenue CAGR 5y | 63.82% | 29.85% |
| EPS CAGR 5y | -3.11% | 46.45% |
| Debt / Equity | - | 0.2x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BBIO leads on
- P/E (TTM)-vs 11.8x+167%
- EV/EBIT-vs 6.4x+124%
- Debt / Equity-vs 0.2x+115%
- Market cap$13.54Bvs $1.75B+87%
HRMY leads on
- ROIC (TTM)12.5%vs -57.94%+122%
- Net margin16.2%vs -125.17%+113%
- EPS CAGR 5y46.45%vs -3.11%+107%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.